TP53 and myelodysplastic syndrome: Somatic mutations of TP53, TET2, and DNMT3A have been shown to identify patients with MDS with shorter OS after allogeneic HSCT [157], suggesting that newer treatment strategies other than transplantation are needed for these patients.